NAD+ Levels Went Up, Outcomes Did Not: What the 2026 Trials Show

NAD+ has one of the cleanest stories in longevity wellness. It is a coenzyme your cells cannot make energy without, it participates in DNA repair, and its levels fall as you age. Raise it back up and you should feel younger. The logic is tidy enough that a whole category of drips, capsules, and subscriptions has been built on it.

In 2026 that logic got its most serious test to date, and the result deserves a careful read rather than a headline.

What the NOPARK trial tested

NOPARK was a phase 3 randomized, double-blind, placebo-controlled trial run across 11 centers in Norway and published in JAMA. It enrolled 410 people with early Parkinson disease, all diagnosed within the previous two years and on stable dopaminergic therapy, and randomized them to oral nicotinamide riboside or placebo for 52 weeks. Nicotinamide riboside is an NAD+ precursor: the body converts it toward NAD+.

The design matters because this was not a small pilot or a biomarker study. It was a year-long trial powered to detect a change in how people with a progressive neurological condition actually function, measured on the Movement Disorder Society Unified Parkinson's Disease Rating Scale.

The biomarker moved. The outcome did not.

On the biochemistry, the compound did its job and then some. Total blood NAD rose markedly in the treatment group, with a mean between-group difference of about 30 micromolar. The NAD+ to NADH ratio rose. Most measured NAD metabolic intermediates rose. If the goal had been to raise NAD+, this would be a success story.

On the clinical outcome, there was no benefit. At week 52 the treatment group's total disease score had increased by 2.45 points while the placebo group's had decreased slightly, an adjusted difference of 2.72 points favoring placebo. That difference reached statistical significance, and it is important to be equally precise about its size: it sits below the 5.2-point threshold generally considered clinically meaningful worsening. Of five key secondary outcomes, only one differed significantly, a non-motor symptom score that also favored placebo.

Safety was not the problem. Serious adverse events occurred in 8.3 percent of the nicotinamide riboside group and 14.1 percent of the placebo group, a difference that was not statistically significant, and overall adverse event rates were similar. The authors' conclusion was plain: the findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease, and did not support it as a symptomatic treatment at the dose and duration tested. Why sustained NAD+ elevation tracked with slightly worse scores remains unexplained; the investigators raised the possibility of an interaction with dopaminergic therapy, and said the mechanisms are not established.

For transparency, the trial medication was supplied by ChromaDex, a Niagen Bioscience company, and some investigators disclosed patents related to nicotinamide riboside in Parkinson disease licensed to that company. Industry-supplied medication in an independently funded trial that reports a null result is, if anything, a mark in favor of the finding.

Target engagement is not a result

There is a term for what NOPARK demonstrated on the biomarker side: target engagement. It means the compound got where it was supposed to go and did what it was supposed to do at the molecular level. Target engagement is a necessary step in drug development and a genuinely good sign early on. It is not an outcome.

This distinction is the single most useful filter to apply to NAD+ marketing. A provider who shows you that your NAD+ level rose has demonstrated target engagement. A provider who shows you that people in your situation functioned or felt measurably better has demonstrated an outcome. Those are different claims, and right now the first one is far easier to make than the second.

What the pooled evidence does support

A 2026 systematic review and network meta-analysis in Frontiers in Nutrition pooled 27 studies covering 1,599 adults to ask a sharper question: effects on what, exactly. Its answer was that NAD+ precursors behave very differently depending on the outcome measured.

• Perceived fatigue and sleep quality: no precursor produced a significant improvement. This is notable, because feeling less tired is the most common reason people try NAD+.
• Endurance performance: nicotinamide mononucleotide showed a dose-dependent effect, with a standardized mean difference of 0.66 at a medium dose and 1.02 at a high dose.
• Neuromuscular strength: unchanged.
• Cognitive performance: the largest signal came from NADH, though the authors flagged that this finding was sensitive to a few influential studies and concentrated in cohorts with existing cognitive impairment.
• Quality of life: a moderate improvement, mainly with nicotinamide mononucleotide.

The authors' recommendation was a precision-based approach that accounts for outcome type, dose, and population characteristics. In other words: NAD+ is not a general-purpose energy fix, and the honest version of the conversation starts by naming the specific thing you are trying to change.

What these trials do not say

Being accurate cuts in both directions, so three limits are worth stating clearly.

First, both lines of evidence examined oral NAD+ precursors. Neither tested intravenous NAD+. You cannot read either result across to an IV session.

Second, NOPARK studied a specific disease population already taking dopaminergic medication. A null or modestly unfavorable result in early Parkinson disease is not evidence about a healthy adult's wellness use, in either direction.

Third, none of this makes IV NAD+ proven. It remains the case that there are no outcome trials showing intravenous or intramuscular NAD+ slows aging or treats any condition, and NAD+ is not FDA approved for any medical use. We offer it inside a wellness framework as something that may support how you feel, and we do not describe it as a treatment or a cure. That language is not legal hedging; it is what the evidence currently licenses us to say.

How to read the next NAD+ headline

1. Ask what was measured. A rise in blood NAD+ is a biomarker. A change in how people function is an outcome. Headlines blur them constantly.
2. Ask who was studied. Results in a disease population do not transfer to healthy adults, and oral results do not transfer to intravenous.
3. Ask how long. Short exploratory studies produced optimistic NAD+ signals that a 52-week trial did not reproduce. Duration changes conclusions.
4. Name your own endpoint. Endurance, quality of life, subjective fatigue, and cognition behaved differently in the pooled data. "More energy" is too vague to evaluate.
5. Prefer supervision over certainty. A clinician who reviews your history and appropriate labs and tells you what is unproven is reading the science correctly.